Evidence map›Paper›PMID 40527301›Full record

ArticleAmerican journal of nephrology2026

Using Machine Learning to Predict Medication Therapy Problems among Patients with Chronic Kidney Disease.

Alaa A Alghwiri, Melanie R Weltman, Linda-Marie U Lavenburg, Zhuoheng Han, Thomas D Nolin, Yi-Fan Chen, Jonathan G Yabes, Manisha Jhamb

Abstract read
In one paragraph

Article in American journal of nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Alaa A AlghwiriRenal-Electrolyte Division, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Melanie R WeltmanDepartment of Pharmacy and Therapeutics, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania, USA.
Linda-Marie U LavenburgRenal-Electrolyte Division, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Zhuoheng HanRenal-Electrolyte Division, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Thomas D NolinRenal-Electrolyte Division, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Yi-Fan ChenDivision of General Internal Medicine, Department of Medicine and Biostatistics, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Jonathan G YabesDivision of General Internal Medicine, Department of Medicine and Biostatistics, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Manisha JhambRenal-Electrolyte Division, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA, jhambm@upmc.edu.

Funding

Translational Pulmonary Vascular BiologyT32HL110849 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Sruti Shiva · 2012 to 2026
$5.0M
PopulAtioN health management to OPTImize Care in CKD (PANOPTIC-CKD)R01DK116957 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI ABDEL-KADER, KHALED A, JHAMB, MANISHA · 2018 to 2022
$3.2M
NHLBI NIH HHS T32 HL110849NIDDK NIH HHS R01 DK116957
6 · The paper itself

Abstract

introductionPatients with chronic kidney disease (CKD) are at risk of medication therapy problems (MTPs) due to high comorbidity and medication burden. Using data from the Kidney Coordinated HeAlth Management Partnership (Kidney CHAMP) trial, we used machine learning to build a predictive model to identify MTP high-risk patients with CKD in the primary care setting.

methodsWe used baseline data from patients enrolled in the intervention arm of the Kidney CHAMP trial, completed May 2019-July 2022, which tested a population health management strategy, including medication management, for improving CKD care. The dataset was divided into 80% training and 20% testing subsets. The area under the ROC curve (AUROC) was used to assess classification accuracy in distinguishing between patients with and without MTP. Eight candidate models were considered, and the top three performing models (random forest, support vector machines, and gradient boosting), based on cross-validated AUROC on training data, underwent further refinement. The model with the highest AUROC in the testing set, while considering the bias/variance trade-off, was selected as the best-performing model. SHapley Additive exPlanations was then leveraged using the best-performing model to evaluate the impact of each predictor to the final risk score.

resultsAmong 730 patients who received medication review at baseline, 566 (77.5%) had at least 1 MTP. Key demographics were mean age 74 years, 55% female, 92% white, 64% with diabetes, and the mean number of medications 5.8 at baseline. The random forest model had the best performance on the testing set with AUROC 0.72, sensitivity 0.80, and specificity 0.64. The five most influential variables, ranked in descending order of importance for predicting individuals with MTP, were diabetes status (yes/no), hemoglobin A1C (HbA1C), urine albumin-to-creatinine ratio (UACR), systolic blood pressure, and age.

conclusionIn outpatient primary care, a machine learning-based MTP risk calculator that uses routinely available clinical data can identify patients with moderate-high-risk CKD who are at high risk for developing MTPs.

Indexed as

Machine LearningRenal Insufficiency, ChronicAgedFemaleHumansMaleMiddle AgedPrimary Health CareRisk AssessmentROC CurveMachine learningMedication therapy problems

Identifiers

PMID40527301
PMCPMC12218150

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.